Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Geratherm Medical AG's Enterprise Value is €7.18 Mil.
Geratherm Medical AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.82 Mil. Therefore, Geratherm Medical AG's EV-to-EBIT ratio for today is -8.78.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Geratherm Medical AG's Enterprise Value is €7.18 Mil.
Geratherm Medical AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €0.34 Mil. Therefore, Geratherm Medical AG's EV-to-EBITDA ratio for today is 21.06.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Geratherm Medical AG (XTER:GME) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Geratherm Medical AG's current Enterprise Value is €7.18 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Geratherm Medical AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.82 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Geratherm Medical AG's current Enterprise Value is €7.18 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Geratherm Medical AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €0.34 Mil.
Geratherm Medical AG's current Enterprise Value is €7.18 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Geratherm Medical AG's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was €16.03 Mil.
Geratherm Medical AG's current Enterprise Value is €7.18 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Geratherm Medical AG's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was €1.30 Mil.
Geratherm Medical AG's current Enterprise Value is €7.18 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Geratherm Medical AG's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €0.71 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Geratherm Medical AG Enterprise Value Related Terms
Geratherm Medical AG Enterprise Value Historical Data
* Premium members only.
The historical data trend for Geratherm Medical AG's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTER:GME vs ABT, SYK, MDT: Enterprise Value Comparison
For the Medical Devices subindustry, Geratherm Medical AG's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Geratherm Medical AG Enterprise Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Geratherm Medical AG's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Geratherm Medical AG's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Geratherm Medical AG's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Geratherm Medical AG (XTER:GME) has a Enterprise Value of €7.18 Mil as of Jul. 31, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Geratherm Medical AG and its competitors.
Is Geratherm Medical AG's Enterprise Value too high?
Geratherm Medical AG's current Enterprise Value is €7.18 Mil. Overall, Geratherm Medical AG has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Geratherm Medical AG's Enterprise Value compare to ABT and SYK?
Geratherm Medical AG's Enterprise Value of €7.18 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Medical Devices & Instruments company?
A good Enterprise Value depends on the Medical Devices & Instruments industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Geratherm Medical AG and its competitors. Geratherm Medical AG's current Enterprise Value is €7.18 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Geratherm Medical AG stock overvalued right now?
Based on GuruFocus' analysis, Geratherm Medical AG (XTER:GME) is currently considered Modestly Undervalued. The stock's GF Value™ is €3.16, compared to a current price of €2.62 — trading 17.1% below its estimated fair value. The current Enterprise Value is €7.18 Mil. Geratherm Medical AG's overall GF Score™ is 72/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Geratherm Medical AG (XTER:GME), the current Enterprise Value is €7.18 Mil as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Geratherm Medical AG (XTER:GME) Overvalued in 2026?
Based on GuruFocus' analysis, Geratherm Medical AG stock appears to be undervalued.
The current stock price of €2.62 is trading 17.1% below its estimated GF Value™ of €3.16.
GuruFocus considers Geratherm Medical AG to be Modestly Undervalued.
Key valuation signals for XTER:GME:
Enterprise Value: €7.18 Mil
GF Value™: €3.16 vs. price of €2.62 (17.1% below fair value)
No single metric tells the full story. See the XTER:GME stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Geratherm Medical AG is a Germany-based medical technology company. The firm operates through four segments: Healthcare Diagnostic, Medical Warming Systems, Cardio/Stroke and Respiratory. Healthcare Diagnostic segment which generates majority revenue provides analog and digital products for measuring body temperature, blood pressure monitors and other products for measuring temperature, as well as related accessories. Medical Warming Systems offers solutions for temperature management at all stages in the pre-clinical and clinical care of the patients, such as rescue situations and operations. Cardio/Stroke segment comprises products for preventing strokes. The Respiratory segment focuses on the development and production of products for pulmonary functional diagnostics.
72GF Score
Get the complete analysis for XTER:GME
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:GME has been successfully added to your 
